Literature DB >> 20545439

Properties of hepatitis C virus minigenome containing mutated 5'UTR region and luciferase transgene.

J Yang1, Y F Lei, Q X An, W Yin, X Lu, L Ye, S H Wei, Z Jia, Z K Xu.   

Abstract

UNLABELLED: Sequences at the 3'UTR of Hepatitis C virus (HCV) negative-strand (-)RNA play an important role in the initiation of positive-strand (+)RNA synthesis. However, the underlying mechanism in cellular context is still unclear. In this report, we designed several cDNA-based HCV-like minigenomes containing different mutations at the 5'UTR of (+)RNA. These (+)RNAs transcribed from the minigenomes in vitro were transfected into HCV replicon cells for producing (-)RNAs with deletions of different stem loops (SL) at the 3'-end. The results showed that expression of the antisense transgene from minigenome increased, when the minigenome containing deletion of SL-C1+D1+E1 at the 3'-end of (-)RNA was transfected into the HCV replicon cells compared to that of the full minigenome. The expression of the transgene from minigenome decreased using other mutant minigenomes containing deletions SL-A1, SL-A1+B1, and SL-A1+B1+C1 at the 3'-end of (-)RNA. Finally, the transgene from SL-C1+D1+E1 of (-)RNA using CMV promoter-driven minigenome was expressed at higher level than full minigenome in HCV replicon cell lines. These results indicated that the region of (-)RNA interacting with HCV replicase may locate in the SL-C1+D1+E1 region of (-)RNA. KEYWORDS: Hepatitis C virus; minigenome; RNA dependent RNA polymerase; replication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20545439     DOI: 10.4149/av_2010_02_105

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  1 in total

1.  Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins.

Authors:  Teymur Kazakov; Feng Yang; Harish N Ramanathan; Andrew Kohlway; Michael S Diamond; Brett D Lindenbach
Journal:  PLoS Pathog       Date:  2015-04-13       Impact factor: 6.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.